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Abstract		
Despite steady vaccination coverage rates, pertussis incidence in the United States has continued 
to rise. This public health challenge has motivated calls for the development of a new vaccine 
with greater efficacy and duration of protection. Any next-generation vaccine would likely come 
at a higher cost, and must provide sufficient health benefits beyond those provided by the current 
vaccine in order to be deemed cost-effective. Using an age-structured transmission model of 
pertussis, we quantified the health and economic benefits of a next-generation vaccine that would 
enhance either the efficacy or duration of protection of the childhood series, the duration of the 
adult booster, or a combination. We developed a metric, the maximum cost-effective price 
increase (MCPI), to compare the potential value of such improvements. The MCPI estimates the 
per-dose price increase that would maintain the cost-effectiveness of pertussis vaccination. We 
evaluated the MCPI across a range of potential single and combined improvements to the 
pertussis vaccine. As an upper bound, we found that a next-generation vaccine which could 
achieve perfect efficacy for the childhood series would permit an MCPI of $18 per dose (95% 
CI: $12–$31). Pertussis vaccine improvements that extend the duration of protection to an 
average of 75 years would allow for an MCPI of $22 per dose for the childhood series (CI: $10–
$33) or $12 for the adult booster (CI: $4–$18). Despite the short duration of the adult booster, 
improvements to the childhood series could be more valuable than improvements to the adult 
booster. Combining improvements in both efficacy and duration, a childhood series with perfect 
efficacy and average duration of 75 years would permit an MCPI of $39 per dose, the highest of 
any scenario evaluated. Our results highlight the utility of the MCPI metric in evaluating 
potential vaccines or other interventions when prices are unknown. 	
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Introduction	
A resurgence of pertussis in the United States (US) has resulted in the highest incidence in over 
half a century [1,2]. Several hypotheses have been postulated to explain the rising incidence [3–
6], with the prevailing view that the increase is attributable to shortcomings in the current 
vaccine series [7,8]. The acellular pertussis (aP) vaccines currently used in the US are the second 
generation of pertussis vaccines, licensed during the 1990s in response to concerns about severe 
side effects associated with whole-cell containing (wP) vaccines [9]. Elevated pertussis in 
adolescents, who represent the first cohorts vaccinated with the aP vaccine, has led to the 
suggestion that the protection conferred by the acellular vaccines wanes faster than that of the 
wP vaccines [10–12]. Additionally, the first doses in the acellular childhood series at 2 and 4 
months confer incomplete protection against disease for infants, who have the highest burden of 
severe pertussis-related disease and mortality [13,14]. Recent studies have demonstrated that 
administration of a maternal pertussis booster vaccine during pregnancy substantially and cost-
effectively reduces disease burden in newborns prior to receipt of their first dose [15–17]. 
Nevertheless, the apparent shortcomings of the current childhood and adult vaccination series 
have renewed interest in a next generation of pertussis vaccine that would provide higher 
efficacy for infants, a longer duration of protection, or both [7,8].	
If such an improved vaccine were brought to market with a price per dose equal to the current 
vaccine, the decision to switch to the new vaccine would be straightforward. However, the 
investment that would be required to develop a new vaccine entails a higher cost per dose than 
that for the current vaccines. Additionally, new recommendations for maternal aP vaccination 
during pregnancy for infant protection[15,16] may render any health benefits of a new vaccine 
insufficient to justify the increased cost. 	
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Cost-effectiveness analysis is often conducted when considering the implementation of a vaccine 
that has already been developed [18–22], or hypothetical vaccines against pathogens for which 
no vaccine exists [23–29]. While—for instance—a study of adding protection against multiple 
pathogens causing otitis media to the pneumococcal vaccine has identified break-even and cost-
effective thresholds in vaccine price [30], no previous analysis has assessed the potential health 
impact and economic value of replacing a current vaccine with an improved hypothetical 
vaccine. With pertussis—and in similar cases where the current vaccine may have multiple 
shortcomings—calculating the relative value of improvements in either duration or efficacy 
could inform the design of a next generation vaccine to optimize public health benefit. 	
Here, we use a previously validated dynamic cost-effectiveness model of B. pertussis 
transmission in the US [17] to evaluate the potential health benefits and economic value of 
developing a next-generation pertussis vaccine. We consider three potential improvements: 1) 
increased efficacy of the childhood vaccination series, 2) extended duration of protection for the 
childhood series, and 3) extended duration of protection for the adult booster, as well as 
combinations of improvements. We formulate the maximum cost-effective price increase 
(MCPI), as a metric of the value of a new vaccine under the constraint that the vaccine remains 
cost-effective. The MCPI metric has general applicability to inform decision-making regarding 
investment in the development and the pricing of potential vaccines.		
Methods	
Transmission Model Structure 	
We modeled the epidemiological states (Figure 1) as susceptible (S), infectious (T: typical 
infection, defined in the Acellular Pertussis Vaccine Trial (APERT) as a cough lasting at least six 
days [31]; A: atypical infection, all other cases), recovered (R), and vaccinated (VP: DTaP 
	6	
vaccination, VB: Tdap vaccination), keeping track of the participation of parents and their infants 
in a program of parental vaccination [17]. A model population of 316 million individuals was 
age-stratified to reflect the 2013 US population [32]. We specified the force of infection for each 
age class based on empirical age-specific social contact rates for the US [33]. We also 
incorporated parents of newborns, and parameterized the extensive contacts that they have with 
their infants based on time-use studies conducted in the US [17,33]. 	
	
Parameterization and Fitting	
Our base case and uncertainty distributions for epidemiological and economic parameters 
(Tables S1, S2) were provided by fitting our model to US incidence data from 2003–2012 [1]. 
We used empirically-derived reporting rates for typical infections for four age groups: 1.38% for 
<1 years, 0.93%  for 1–6 years, 0.45%  for 7–10 years, and 0.30% for 11+ years) [17]. We 
assumed that the less severe atypical cases were neither hospitalized nor reported.	
	
Scenarios of Next-Generation Pertussis Vaccines	
Scenarios for improvement of the pertussis vaccine included: 1) increasing the efficacy of the 
childhood vaccination series, 2) extending the duration of protection for the childhood series, and 
3) extending the duration of protection for the adult booster.	
We define efficacy, E, as the proportional reduction in the risk of infection for vaccinated 
individuals relative to that of a susceptible, unvaccinated individual [34]. We parameterize the 
efficacy of each of the first three doses of the pertussis vaccine using data from a case-control 
study [13]. These case-control studies characterize effectiveness rather than efficacy at the time 
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of vaccination; however, under the assumption that no waning occurs in the time between the 
administration of each of the three primary doses, vaccine effectiveness and efficacy are 
equivalent. Efficacy for the fourth and fifth dose was calculated previously [17] by 
simultaneously fitting both efficacy and duration to case-control data [12,13]. To model an 
improvement to efficacy, we simultaneously increased the efficacy of each dose by a factor p, 
such that	
!"($) = 1 − (1 − !(($))	/	+,	
where E(i)n is the efficacy of a the ith dose of the next-generation vaccine, and E(i)c is the efficacy 
of the ith dose for the current vaccine. Protection from the fourth and fifth doses of the childhood 
series is estimated to be complete prior to waning, as is protection from the adolescent and adult 
booster [17]. We evaluated our model across a range of first-dose efficacy from its current 
estimated value, 0.55, up to a perfect efficacy of 1. 	
Waning of efficacy was modeled as an exponential function, with a base case average duration of 
25 years for the complete childhood series [12,17], and 2.7 years for each adult booster [17]. 
These ‘durations’ are modeled as the inverse of the waning rate, and were calculated previously 
by fitting to case-control data [11,12,17]. They are consistent with waning rates estimated by 
others [35,36]. The exponential waning process in the model does not yield complete protection 
for all individuals for the duration. Indeed, with an average duration of immunity of 25 years, 
nearly one-third of vaccinated individuals will have lost their immunity within 10 years of their 
most recent dose. No matter the duration, waning begins immediately following vaccination, 
following a “deterioration” model [37]. Next generation vaccines were evaluated for average 
durations of protection up to 75 years for both childhood and adult vaccination. Given that the 
intervals between the first four doses of the childhood series are much shorter than the average 
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duration of protection conferred and that series completion rates are high, changes to the duration 
of protection will not greatly benefit infants before receipt of the fourth dose. Therefore, we 
assumed improvements regarding the duration of protection apply to the final two doses in the 
childhood series (VP4 & VP5) and/or the adult booster (B). Additionally, we evaluated scenarios 
of simultaneous improvement in the efficacy and duration of the childhood series, as well as a 
scenario of simultaneous improvement in the duration of protection for both the childhood and 
adult boosters.	
We modeled the current childhood schedule of doses at 2, 4, 6, and 18 months, and 5 years old 
[38]. We also included an adolescent booster at 12 years old and a booster for women during the 
third trimester of each pregnancy [39,40]. We applied current estimates of coverage in the US for 
the childhood series and the adolescent booster [41]. Coverage estimates for Tdap during 
pregnancy in the US vary substantially across studies, from less than 20% [42] to over 80% [43]. 
In our base case, coverage for maternal vaccination was set at 50%. A coverage of 50% is 
currently achieved in pregnant women for the influenza vaccine [44], which has been 
recommended for pregnant women in the US since 2004. Our sensitivity analysis considers the 
outcomes at both higher and lower coverage levels for maternal vaccination. In our model, U.S. 
maternal vaccination begins in 2013.	
We compared the predictions for 2020–2030 with each next-generation vaccine against 
predictions for the same time period retaining the current vaccine. Consistent with US 
demographic trends, we specified four million infants be born annually and become eligible for 
pertussis vaccination [45].	
	
Maximum Cost-Effective Price Increase	
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According to cost-effectiveness criteria set by the World Health Organization (WHO), an 
intervention is considered “cost-effective” if it confers health benefits at a cost less than three 
times the per-capita gross domestic product (GDP) per life-year [46]. For the US in 2013, this 
threshold is $159,429. Following this criterion, the maximum cost-effective price increase 
(MCPI) for a next generation booster would be:	
,	×	.	/	01  ,	
where Q is the number of quality-adjusted life-years (QALYs) saved through use of a new 
vaccine, w is the willingness-to-pay for life-years, M is the economic savings from reduced 
medical costs of disease, and d is the number of vaccine doses that are delivered. Indirect costs 
associated with vaccination or disease are not included here, but would be considered a 
component of M.  While improved efficacy pertains only to the primary three doses of the 
childhood series, and improved duration pertains only to the fourth and fifth doses of the 
childhood series, the cost increase is assumed to be spread across all five doses of the series. 
Costs and QALYs were discounted by 3% annually over the decade time frame [46], but costs 
and QALYs were assumed constant over the period prior to implementation of the next-
generation vaccine. Therefore, all costs are presented in 2013 $US.	
	
Results	
We found that improved efficacy of the vaccine doses in the childhood pertussis series would 
provide nearly linear gains in health and economic returns. For example, an increase in the 
efficacy of the first dose from 0.55 to 0.75, with proportional increases in the efficacies of other 
childhood doses, would provide an average gain of 900 QALYs annually during the first 10 
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years following implementation (Figure 2, Table 2), averting $5.7 million in health expenditures 
annually. If the first dose of the childhood series were perfectly efficacious, it would provide an 
average gain of 2100 QALYs annually over a decade and health savings of $12.9 million 
annually. These gains provide an upper bound for what a vaccine with improved efficacy could 
do: the maximum cost-effective price increase (MCPI) per dose would be $8 per dose with a 
first-dose efficacy of 75%, and $18 for 100% efficacy.	
In contrast to improvements in vaccine efficacy, extension of the vaccine duration of protection 
provided by the childhood series exhibited diminishing marginal returns. Increasing the average 
duration of protection conferred by the childhood series from 25 years to 50 years would provide 
an average annual gain of 1800 QALYs and annual health savings of $6.3 million. In 
comparison, extending the average duration further to 75 years would provide an average annual 
gain of 2600 QALYs and an annual health savings of $8.7 million. The MCPI per dose for a 
more durable childhood vaccine would be $16 for a duration of 50 years, and $22 for a duration 
of 75 years. Largely due to the uncertainty surrounding the protective duration of the current 
vaccine, the lower bounds for the 95% confidence intervals on QALYs gained and of the MCPI 
are not positive until the duration of protection of the next-generation vaccine reaches 
approximately 35 years.	
Extension of the average duration of the adult booster from 2.7 years to 30 years would provide 
an annual gain of 300 QALYs and annual health savings of $1.3 million. The benefits of 
increasing the duration of protection for the adult booster quickly plateau. Extension of its 
duration by an additional 45 years, to 75 years, provides an annual gain of 400 QALYs and an 
annual health savings of $1.5 million: an increase of only 100 QALYs and $200,000 annually 
despite the fact that the duration has been extended by an additional 45 years. Following the 
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same trend, the MCPI per dose would be $11 for a duration of 30 years, and only modestly 
increases to $12 for a vaccine with an average duration of 70 years.	
Concurrent improvement to both the efficacy and duration of the childhood vaccine predictably 
achieves the maximum health benefit of all scenarios tested (Figure 3b, 3d). The combination of 
improvements that achieves both the greatest health benefits and the highest MCPI would be a 
childhood series with perfect efficacy and a 75-year average duration of protection, which could 
provide an average annual gain of 4600 QALYs at an MCPI of $39. Improving the duration of 
both the childhood and adult vaccine also has the potential to achieve greater health benefits than 
improvement in any single factor, and could warrant a higher price (Figure 3a, 3c). However, the 
MCPI for any combination of improvements is less than the sum of the individual MCPIs for the 
improvements which make up the combination.	
The MCPI is sensitive to the societal willingness-to-pay (WTP) for QALYs. For improvements 
to childhood vaccine efficacy, the MCPI at a willingness-to-pay of $0 per QALY is 
approximately 4% of the MCPI at a WTP of $150,000 per QALY (Figure 4), indicating that 
nearly all of the value for this improvement is derived from QALY benefits rather than monetary 
health savings. The MCPI for extended duration is also sensitive to WTP. The value of the MCPI 
is robust to shifts of maternal vaccination coverage, particularly to any expansion above the 
current coverage of 15% (Supplementary Figure 1).	
	
Discussion	
We have performed the first quantitative analysis of the potential utility and value of introducing 
a next-generation vaccine. Increasing the efficacy of the childhood pertussis vaccine series, 
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extending the duration of protection of the childhood vaccines, or extending duration of 
protection for the adolescent and adult boosters could all improve health and avert medical costs 
as stand-alone improvements or in combination. The singular improvement to pertussis vaccines 
that would provide both the greatest potential health benefit and the greatest economic benefit 
would be extending the duration of protection of the childhood vaccine series. Increasing the 
efficacy of the childhood series could also provide substantial benefit; however, the benefits of 
extending the duration of protection of the adult booster would not convey as much benefit as 
would be conveyed by improvements to the childhood series. The combination of improving the 
childhood series to perfect efficacy and an average 75-year duration of protection achieves both 
the largest health benefits and the highest MCPI, $39. This MCPI represents the upper bound of 
a cost-effective price increase for a new vaccine. 	
Given that the average duration of protection for the adult booster is less than 3 years, it might be 
expected that the improvements to the duration of protection for the adult booster would yield 
the greatest returns. Indeed, our results demonstrate that small improvements to the durability of 
the adult booster vaccine would be more valuable than an equivalent improvement to the 
childhood series. However, the benefits of extending protection of the adult booster quickly 
plateau, and are eclipsed by the benefits of improving the efficacy and duration of the childhood 
series. For example, a five-year extension of protection to the adult booster would convey greater 
value than a five-year extension to the childhood series. In contrast, a 25-year extension of 
protection of the childhood series would have greater health and economic impacts than a 25-
year extension to the adult booster. These results provide insight into the potential returns on 
technological development. 	
There is considerable uncertainty surrounding the duration of protection of the childhood series 
[12]. We have incorporated the uncertainty regarding this parameter in our analysis, conveying 
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insight into the minimum improvement in duration of protection that would be necessary for the 
next-generation vaccine to be economically valuable. At a 35-year duration of protection the 
lower 95% confidence interval becomes positive, indicating that a price increase based on 
extended durability may only be justifiable if the new childhood series demonstrably exceeds 
this mark. In contrast, small improvements to the duration of protection of the adult booster and 
to the efficacy of the childhood series quickly and confidently generate a positive MCPI. Health 
and economic outcomes quantified by the epidemiological model underlying this analysis are 
robust to reasonable variation in diverse other epidemiological parameters such as the duration of 
natural immunity, the relative infectiousness of an asymptomatic case compared to a typical one, 
social contact rates, and others [17].	
 Exponential waning of protection models individual heterogeneity, whereby some individuals 
lose their immunity almost immediately and others retain protection for considerably longer than 
the mean. Indeed, under our base case estimate that the duration of the childhood series has a 
mean of 25 years, nearly one-third of vaccinated individuals have lost their immunity within 10 
years of their most recent dose. This duration of protection leaves considerable room for 
improvement. For example, with a mean duration of protection of 75 years, less than 15% of 
individuals would lose their immunity within 10 years of their most recent dose.	
Maternal vaccination during pregnancy has been shown to significantly reduce the risk of 
pertussis infection in newborns [15]. Despite the strong protection conferred by maternal 
vaccination to infants, our results are robust to changes in maternal vaccination coverage. This 
robustness is largely attributable to the benefits of maternal vaccination for infants under two 
months old. This newborn age class is largely unaffected by the improvements investigated here 
as they remain unvaccinated. 	
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Recent studies suggest that Bordetella pertussis may be evolving antigenically to evade 
protection by the current vaccine [47]. As resistant Bordetella pertussis pathogens proliferate, the 
efficacy and duration of the the current vaccine will be further reduced. A next-generation 
pertussis vaccine could specifically alleviate these issues. Alternatively, the current generation of 
vaccine might be improved in ways that are not captured by higher efficacy and longer duration. 
Recent studies in non-human primates have shown that aP vaccines protected subjects from 
typical whooping cough disease but not ongoing transmission [48][49][48] Above all, to be 
considered acceptable for implementation, any next-generation vaccine would have to 
demonstrate the same or greater vaccine safety profile compared to existing vaccines.	
New vaccines against pertussis are under active development. A phase I clinical trial recently 
demonstrated the safety of a live-attenuated nasal pertussis vaccine based on the BPZE1 strain 
[50]. Mouse studies suggest that this vaccine might have higher efficacy in infants than the 
current acellular vaccine [51]. If perfect efficacy could be achieved at the first infant dose, the 
MCPI of this new vaccine would be $18. If the vaccine improved duration of protection as well, 
a higher price would be warranted. Identification of alternative vaccine candidates is ongoing 
[52,53]. As yet, information regarding the potential efficacy or waning of these candidates is 
unavailable.	
Economic predictions for future vaccines have focused on the potential cost-effectiveness of 
introducing vaccination where none currently exists [19,20,25,28]. Our analysis provides the first 
quantification of the value of replacing an existing vaccine with a hypothetical higher-cost, 
higher-performing option. The metric we have developed, the maximum cost-effective price 
increase (MCPI), is readily applicable to analyses of improvements to vaccines against other 
diseases. Such analyses could be informative for many different stakeholders in vaccinology. 
Scientists can be guided to the most impactful avenues for research. On the other hand, the 
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vaccine with the highest MCPI does not necessarily provide the greatest health benefits. For 
example, if the willingness-to-pay for QALYs was sufficiently low, and if the medical costs of 
disease treatment in a population subset were sufficiently high, the vaccine with the highest 
MCPI would not align with the vaccine providing the greatest health benefits. Manufacturers 
gain information about potential investments and avoid fruitless expenditure. Using MCPI, 
manufacturers and purchasers can enter into price negotiations with more complete information, 
enabling a more efficient and transparent market. Most importantly, patients will receive the 
direct health benefits from an improved next-generation pertussis vaccine.	
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Table 1: Current vaccine parameter values and ranges evaluated for next-generation 
vaccine improvements.  	
Parameter	 Current Value	 Tested Range	
Effectiveness of Infant Series*	 	 	
Dose 1	 0.55	 0.55–1.0	
Dose 2	 0.75	 0.75–1.0	
Dose 3	 0.84	 0.84–1.0	
Efficacy of Childhood Boosters	 0.98	 0.98–1.0	
Duration of Childhood Series	 25 years	 25–75 years	
Duration of Adolescent/Adult Booster	 2.7 years	 2.7–75 years		
*In predictions, the first three doses in the childhood series are improved simultaneously. See 
Methods for details. 	
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Table 2: Impact of Individual Improvements for a Next-Generation Vaccine. QALYs, costs, 
and infant deaths are presented here as annual undiscounted averages. QALYs and costs were 
discounted at a rate of 3% annually in the calculation of the maximum cost-effective price 
increase (MCPI).	
Improvement	 Value	 QALYs 
gained	
(95% CI)	 Medical Cost Savings, in $US millions 	
(95% CI)	
Infant Deaths 
Averted 
Annually	
(95% CI)	
Maximum 
Cost-Effective 
Price Increase	
(95% CI)	
Efficacy of 
Childhood Series	 0.6	 200	(30–1400)	 1.4	(0.8–7.5)	 0.3	(0.1–1.3)	 $2	($0–$12)	
0.75	 900	
(600–2300)	 5.7	(4.8–19.0)	 1.4	(0.9–2.6)	 $8	($5–$19)	
0.9	 1600	
(1100–3100)	 10.0	(8.2–31.3)	 2.5	(1.7–4.2)	 $14	($9–$26)	
1	 2100	
(1400–3600)	 12.9	(10.4–39.3)	 3.2	(2.1–5.3)	 $18	($12–$31)	
Duration of 
Protection for 
Childhood Series	 30	 600	(-400–1700)	 1.9	(-0.7–3.7)	 0.3	(-0.3–1.0)	 $5	(–$4–$14)	
50	 1800	
(600–3100)	 6.3	(0.3–8.0)	 1.1	(0.5–1.7)	 $16	($5–$26)	
75	 2600	
(1200–4000)	 8.7	(0.5–10.9)	 1.5	(0.9–2.1)	 $22	($10–$33)	
Duration of 
Protection for 
Adolescent/Adult 
Booster	
10	 200	
(80–300)	 0.8	(0– - 1.0)	 0.2	(0.1–0.2)	 $7	($2–$10)	
30	 300	
(100–500)	 1.3	(0.1–1.8)	 0.3	(0.1–0.3)	 $11	($4–$16)	
50	 400	
(100–600)	 1.4	(0.1–1.9)	 0.3	(0.1–0.3)	 $12	($4–$17)	
75	 400	
(200–600)	 1.5	(0.1–2.0)	 0.3	(0.1–0.4)	 $12	($4–$18)	
Figure 1: Dynamic Transmission Model Schematic.	
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Figure 2: QALY impact and Maximum Cost-Effective Price Increase for three types of 
next-generation vaccine. Solid lines depict the base case. Dashed lines bound the 95% 
confidence interval. QALYs gained (panels A-C, undiscounted annual mean) and the MCPI 
(panels D-F, costs and QALYs discounted at 3% annually) are shown for improvements to the 
efficacy of the childhood vaccine (panels A and D), the duration of the childhood vaccine (panels 
B and E), and the duration of the adult booster (panels C and F). For improvements to the 
efficacy of the childhood series, the efficacy of all doses in the series improves in tandem with 
improvement to the first dose.	
	
Figure 3: Contour plot of Maximum Cost-Effective Price Increase for next-generation 
vaccines with combinations of improvements. Contours correspond to the MCPI for improved 
efficacy and extended duration of the childhood vaccine (A) or for improved duration of both the 
childhood and adult vaccines (B). For improvements to the efficacy of the childhood series, the 
efficacy of all doses in the series improves in tandem with improvement to the first dose.	
	
Figure 4: Sensitivity of MCPI to societal willingness-to-pay for QALYs. Each dotted or 
dashed represents the maximum cost-effective price-increase ($US) of a single improvement to 
the pertussis vaccine across varying values for the societal willingness-to-pay for QALYs, a 
value which corresponds to the threshold for cost-effectiveness. The vertical solid gray line 
indicates the World Health Organization threshold for cost-effectiveness in the US context: 
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$159,429 per QALY. For improvements to the efficacy of the childhood series, the efficacy of all 
doses in the series improves in tandem with improvement to the first dose.	
	
Supporting Information	
Figure S1: Sensitivity of MCPI to maternal vaccination coverage. Each line represents the 
maximum cost-effective price increase ($US) of a single improvement to the pertussis vaccine 
across varying values of maternal vaccination coverage. For improvements to the efficacy of the 
childhood series, the efficacy of all doses in the series improves in tandem with improvement to 
the first dose.	
	
Table S1:  Epidemiological Model Parameters	
Table S2:  Historical Vaccination Coverage 	
Table S3:  Health and Economic Outcome Parameters	
	
	 	
	21	
	
References	
[1] Pertussis (Whooping Cough) Surveillance and Reporting. Centers for Disease Control and 
Prevention n.d. http://www.cdc.gov/pertussis/surv-reporting.html (accessed July 16, 2015).	
[2] Skoff TH, Cohn AC, Clark TA, Messonnier NE, Martin SW. Early Impact of the US Tdap 
vaccination program on pertussis trends. Arch Pediatr Adolesc Med 2012;166:344–9.	
[3] Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of 
pertussis. Science 2010;330:982–5.	
[4] Riolo MA, King AA, Rohani P. Can vaccine legacy explain the British pertussis resurgence? 
Vaccine 2013;31:5903–8.	
[5] Rohani P, Pejman R, Earn DJD, Grenfell BT. Pertussis transmission in England and Wales. Lancet 
2000;355:1553–4.	
[6] Mooi FR. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic 
pathogen. Infect Genet Evol 2010;10:36–49.	
[7] Ausiello CM, Cassone A. Acellular Pertussis Vaccines and Pertussis Resurgence: Revise or 
Replace? MBio 2014;5:e01339–14 – e01339–14.	
[8] Edwards KM. Unraveling the challenges of pertussis. Proc Natl Acad Sci U S A 2014;111:575–6.	
[9] Allen A. The Pertussis Paradox. Science 2013;341:454–5.	
[10] Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California pertussis 
epidemic, 2010. J Pediatr 2012;161:1091–6.	
[11] Koepke R, Eickhoff JC, Ayele RA, Petit AB, Schauer SL, Hopfensperger DJ, et al. Estimating the 
effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: 
evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis 
2014;210:942–53.	
[12] Misegades LK, Kathleen W, Kathleen H, John T, Messonnier NE, Clark TA, et al. Association of 
Childhood Pertussis With Receipt of 5 Doses of Pertussis Vaccine by Time Since Last Vaccine 
Dose, California, 2010. JAMA 2012;308:2126.	
[13] Quinn HE, Snelling TL, Macartney KK, McIntyre PB. Duration of protection after first dose of 
acellular pertussis vaccine in infants. Pediatrics 2014;133:e513–9.	
[14] Centers for Disease Control and Prevention (CDC). Pertussis--United States, 2001-2003. MMWR 
Morb Mortal Wkly Rep 2005;54:1283–6.	
[15] Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al. Effectiveness of 
maternal pertussis vaccination in England: an observational study. Lancet 2014;384:1521–8.	
[16] Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, et al. A case-control 
study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in 
England and Wales, 2012-2013. Clin Infect Dis 2015;60:333–7.	
[17] Atkins KE, Fitzpatrick MC, Galvani AP, Townsend JP. Cost-effectiveness of pertussis vaccination 
during pregnancy in the US. American Journal of Epidemiology n.d.	
[18] Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS. Cost-effectiveness and economic benefits 
of vaccines in low- and middle-income countries: a systematic review. Vaccine 2012;31:96–108.	
[19] Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological 
dynamics in England and Wales. Vaccine 2012;30:552–64.	
[20] Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza 
vaccine. Vaccine 2012;30:7443–6.	
[21] Fitzpatrick MC, Hampson K, Cleaveland S, Mzimbiri I, Lankester F, Lembo T, et al. Cost-
Effectiveness of Canine Vaccination to Prevent Human Rabies in Rural Tanzania. Ann Intern Med 
2014;160:91–100.	
[22] Paternina-Caicedo A, De la Hoz-Restrepo F, Alvis-Guzmán N. Epidemiological and Economic 
	22	
Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A 
Cost-effectiveness Modeling Analysis. Pediatr Infect Dis J 2015;34:e176–84.	
[23] Gessner BD. The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the 
elderly. Vaccine 2000;18:1485–94.	
[24] Berndt ER, Glennerster R, Kremer MR, Lee J, Levine R, Weizsäcker G, et al. Advance market 
commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health 
Econ 2007;16:491–511.	
[25] de Vries R, Klok RM, Brouwers JRBJ, Postma MJ. Cost-effectiveness of a potential future 
Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health. 
Vaccine 2009;27:846–52.	
[26] Massad E, Coutinho FAB, Chaib E, Burattini MN. Cost-effectiveness analysis of a hypothetical 
hepatitis C vaccine compared to antiviral therapy. Epidemiol Infect 2009;137:241–9.	
[27] Meijboom MJ, Pouwels KB, Luytjes W, Postma MJ, Hak E. RSV vaccine in development: assessing 
the potential cost-effectiveness in the Dutch elderly population. Vaccine 2013;31:6254–60.	
[28] Durham DP, Ndeffo Mbah ML, Medlock J, Luz PM, Meyers LA, Paltiel AD, et al. Dengue 
dynamics and vaccine cost-effectiveness in Brazil. Vaccine 2013;31:3957–61.	
[29] Mirelman AJ, Ballard SB, Saito M, Kosek MN, Gilman RH. Cost-effectiveness of norovirus 
vaccination in children in Peru. Vaccine 2015;33:3084–91.	
[30] O’Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, et al. New vaccines 
against otitis media: projected benefits and cost-effectiveness. Pediatrics 2009;123:1452–63.	
[31] Ward JI, Cherry JD, Chang S-J, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis 
vaccine among adolescents and adults. N Engl J Med 2005;353:1555–63.	
[32] United States Census Bureau, Population Estimates n.d. 
http://www.census.gov/popest/data/historical/2010s/vintage_2013/national.html (accessed 
September 30, 2015).	
[33] Zagheni E, Billari FC, Manfredi P, Melegaro A, Mossong J, Edmunds WJ. Using time-use data to 
parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 
2008;168:1082–90.	
[34] Shim E, Galvani AP. Distinguishing vaccine efficacy and effectiveness. Vaccine 2012:6–11.	
[35] Wearing HJ, Rohani P. Estimating the duration of pertussis immunity using epidemiological 
signatures. PLoS Pathog 2009;5:e1000647.	
[36] Gambhir M, Clark T a., Cauchemez S, Tartof SY, Swerdlow DL, Ferguson NM. A Change in 
Vaccine Efficacy and Duration of Protection Explains Recent Rises in Pertussis Incidence in the 
United States. PLoS Comput Biol 2015;11:e1004138.	
[37] Kanaan MN, Farrington CP. Estimation of waning vaccine efficacy. J Am Stat Assoc 2002;97:389–
97.	
[38] Immunization Schedules. Centers for Disease Control and Prevention 2015. 
http://www.cdc.gov/vaccines/schedules/index.html (accessed July 20, 2015).	
[39] Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, et al. Preventing 
tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid 
and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization 
Practices (ACIP). MMWR Recomm Rep 2006;55:1–34.	
[40] Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus 
toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--
Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 
2013;62:131–5.	
[41] Elam-Evans LD, Yankey D, Jeyarajah J, Singleton JA, Curtis RC, MacNeil J, et al. National, 
regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--
United States, 2013. MMWR Morb Mortal Wkly Rep 2014;63:625–33.	
[42] Kharbanda EO, Vazquez-Benitez G, Lipkind H, Naleway AL, Klein NP, Cheetham TC, et al. 
Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink Sites. Prev Med 
2014;67:316–9.	
[43] Goldfarb IT, Little S, Brown J, Riley LE. Utilization of the combined tetanus-diphtheria and 
	23	
pertussis vaccine during pregnancy. Am J Obstet Gynecol 2014. doi:10.1016/j.ajog.2014.05.029.	
[44] Ding H, Black CL, Ball S, Donahue S, Fink RV, Williams WW, et al. Influenza vaccination 
coverage among pregnant women--United States, 2014-15 influenza season. MMWR Morb Mortal 
Wkly Rep 2015;64:1000.	
[45] Age and Sex Composition in the United States: 2012. United States Census Bureau 2013. 
http://www.census.gov/population/age/data/2012comp.html (accessed July 20, 2015).	
[46] Sachs J, World Health Organization. Macroeconomics and Health: Investing in Health for Economic 
Development. Diamond Pocket Books (P) Ltd.; 2001.	
[47] Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, et al. Global population structure 
and evolution of Bordetella pertussis and their relationship with vaccination. MBio 2014;5:e01074.	
[48] Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail 
to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A 
2014;111:787–92.	
[49] Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of Bordetella pertussis. 
BMC Med 2015;13:146.	
[50] Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergström J, Ljungman M, et al. A phase I 
clinical study of a live attenuated Bordetella pertussis vaccine-BPZE1; a single centre, double-blind, 
placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male 
volunteers. PLoS One 2014;9:e83449.	
[51] Mielcarek N, Nathalie M, Anne-Sophie D, Dominique R, Julie B, Carine R, et al. Live Attenuated B. 
pertussis as a Single-Dose Nasal Vaccine against Whooping Cough. PLoS Pathog 2006;2:e65.	
[52] Gouw D de, de Gouw D, de. Jonge MI, Hermans PWM, Hans J C, Aldert Z, et al. Proteomics-
Identified Bvg-Activated Autotransporters Protect against Bordetella pertussis in a Mouse Model. 
PLoS One 2014;9:e105011.	
[53] Alvine T, Ganske A, Nilles M, Bradley D. BscF as a vaccine candidate for Bordetella pertussis 
infection (“Whooping Cough”)(VAC9P. 1064). The Journal of Immunology 2015;194:145–144.		
⌧N
1
⌧V
1
 A
1
 T
1
(1  ✏P1)
1
 B
1
 P
1
 
1
(1  ✏P2)
1
 
1
(1  ✏P3)
1
 
1
(1  ✏P4)
1
 
1
(1  ✏P5)
1
 
1
(1  ✏B)
1
 
1
 
1
⌧B
1
f
1
 
1
1   
1
S
VP5
VP4
VP3
VP2
VP1
VB
T
A
R
0.6 0.7 0.8 0.9 1.0-
10
00
10
00
30
00
Efficacy of 1st infant dose
Q
A
LY
s 
ga
in
ed
 a
nn
ua
lly
A
30 40 50 60 70-
10
00
10
00
30
00
Duration of childhood series (years)
B
10 20 30 40 50 60 70-
10
00
10
00
30
00
Duration of adult booster (years)
C
0.6 0.7 0.8 0.9 1.0
-1
0
0
10
20
30
40
Efficacy of 1st infant dose
M
C
P
I (
$U
S
)
D
30 40 50 60 70
-1
0
0
10
20
30
40
Duration of childhood series (years)
E
10 20 30 40 50 60 70
-1
0
0
10
20
30
40
Duration of adult booster (years)
F
A B C
D E F
Duration of childhood series (years)
E
ffi
ca
cy
 o
f 1
st
 in
fa
nt
 d
os
e
30 40 50 60 70
0.
6
0.
7
0.
8
0.
9
1.
0
Duration of childhood series (years)
D
ur
at
io
n 
of
 a
du
lt 
bo
os
te
r (
ye
ar
s)
30 40 50 60 70
10
20
30
40
50
60
70
A B
0
5
10
15
20
25
30
A) 1st Dose Efficacy
Willingness-to-pay ($US)
M
C
P
I (
$U
S
)
$0 $100,000 $200,000
0.9
0.75
0.6
0
5
10
15
20
25
30
B) Duration of Childhood Series
Willingness-to-pay ($US)
$0 $100,000 $200,000
75 years
50 years
30 years
0
5
10
15
20
25
30
C) Duration of Adult Booster
Willingness-to-pay ($US)
$0 $100,000 $200,000
75 years
50 years
30 years
 1 
COST-EFFECTIVENESS OF NEXT-GENERATION 
VACCINES: THE CASE OF PERTUSSIS 
SUPPLEMENTARY MATERIAL 
Meagan C. Fitzpatrick, Natasha S. Wenzel, Samuel V. Scarpino, Benjamin M. Althouse, Katherine 
E. Atkins, Alison P. Galvani, Jeffrey P. Townsend 
 
 
TABLE OF CONTENTS 
Figure	S1:	Sensitivity	of	MCPI	to	maternal	vaccination	coverage	....................................	2	
Table	S1:		Epidemiological	parameters	.....................................................................................	3	
Table	S2:		Historical	Vaccination	Coverage	Rates	..................................................................	4	
Table	S3:		Health	and	Economic	Outcome	Parameters	.........................................................	5	
Bibliography	........................................................................................................................................	6	
 
 
  
 2 
Figure S1: SENSITIVITY OF MCPI TO MATERNAL VACCINATION COVERAGE  
Each line represents the maximum cost-effective price increase ($US) of a single improvement 
to the pertussis vaccine across varying values of maternal vaccination coverage. For 
improvements to the efficacy of the childhood series, the efficacy of all doses in the series 
improves in tandem with improvement to the first dose. 
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TABLE S1:  EPIDEMIOLOGICAL PARAMETERS 
 
Parameter Symbol Base Case (95% CI) Reference 
Birth Rate f 0.05 [1] 
Efficacy of maternally-acquired antibodies m 0.89 (0.77 – 0.93) [1] 
Probability of infection, given exposure (per minute) b 0.0031 (0.0024 – 0.0041) [1] 
Probability of typical infection, given infection σ 0.195 [2,3] 
Duration of typical infection (days) 1/ϒT 25 (21 – 28) [4,5] 
Duration of atypical infection (days) 1/ϒA 8 (4 – 10) [4,5] 
Relative transmissibility of typical infection  1 [1] 
Relative transmissibility of atypical infection ρ 0.1 [1] 
Duration of natural immunity (years) 1/τN 30 [1,6]  
DTaP    
1st dose efficacy ε1 0.55 (0.45 – 0.62) [7] 
2nd dose efficacy ε2 0.75 (0.66 – 0.82) [7] 
3rd dose efficacy ε3 0.84 (0.79 – 0.87) [7] 
4th/5th dose efficacy εV 1.00 (0.98 – 1.00) [8] 
Duration of vaccine-induced immunity τV 23.5 (17.2 - 35.7) [8] 
Tdap    
Efficacy εB 1.00 (0.86 – 1.00) [1,9] 
Duration of vaccine-induced immunity τB 2.7 (2.1 - 3.8) [1,9] 
    
Reporting Rate of Typical Cases (%)    
<1 year old  1.38 [1,3,10] 
1-6 years old  0.93 [1,3,10] 
7-10 years old  0.45 [1,3,10] 
11+ years old  0.3 [1,3,10] 
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TABLE S2:  HISTORICAL VACCINATION COVERAGE 
Coverage compiled from [11,12]. 
 
Doses Years Symbol Coverage Rates (95% CI) 
Doses 1-3, childhood series 1900-1945 ϕP1-3 0 
 1946-1994  70 (69 - 71) 
 1995-predictions  95 (94 - 96) 
Dose 4, childhood series 1900-1969 ϕP4 0 
 1970-1994  70 (69-71) 
 1995-predictions  85 (84-85) 
Dose 5, childhood series 1900-1969 ϕP5 0 
 1970-1994  70 (69-71) 
 1995-predictions  95 (94-96) 
Adolescent/Adult Booster* 2006 ϕB 51.9 
 2007  65.2 
 2008  73.7 
 2009  81 
 2010-predictions  85.3 
 
*Booster administered to 12-year-olds starting in 2006, per CDC recommendation [13]  
 5 
TABLE S3:  HEALTH AND ECONOMIC OUTCOME PARAMETERS 
 
Age Outcome 
Probability of 
Outcome, as 
reported 
QALY weight, until 
improvement 
QALY weight, 
improvement to 
recovery 
Time to 
Improvement 
(days) 
Time to 
Recovery 
Direct Medical 
Cost, US$2013 References 
Infant Unknown, Unreported 0 0.9 1 35 75 0 [1,14] 
 Outpatient 0.79 0.85 0.9 35 75 129 [1,14,15] 
 Hospitalization 0.19 0.58 0.9 35 75 8553 [15–17] 
 Neurological 
Disease 0.012 0.51 0.9 35 75 8213 [14,15,17,18] 
 Death 0.008 0 0 NA NA 18463 [1,15,18–20] 
Older Unknown, Unreported 0 0.9 1 21 66 0 [14,15] 
 Moderate 
Outpatient 0.31 0.85 0.9 21 66 320 [14,15,17,21] 
 Severe 
Outpatient 0.66 0.81 0.9 21 66 445 [14,15,17,21] 
 Hospitalization 0.03 0.82 0.9 21 66 3435 [17,21] 
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